Targeting menin for precision therapy in high-risk acute myeloid leukemia

被引：1

作者：

Jamil, Abdur ^{[1
]}

Qureshi, Zaheer ^{[2
]}

El-amir, Zain Mary ^{[3
]}

Kupakuwana-Suk, Gillian ^{[4
]}

Akram, Hamzah ^{[5
]}

Ahmad, Mohsin ^{[6
]}

Huselton, Eric ^{[7
]}

机构：

[1] Samaritan Med Ctr, Dept Med, Watertown, NY 13601 USA

[2] Quinnipiac Univ, Frank H Netter MD Sch Med, Bridgeport, CT USA

[3] Univ Michigan, Ann Arbor, MI USA

[4] Univ Ottawa, Ottawa Hosp, Leukemia Fellowship Program, Dept Med,Div Hematol, Ottawa, ON, Canada

[5] Hamilton Hlth Sci, Hamilton, ON, Canada

[6] CHRISTUS Southeast Texas St Elizabeth Hosp, Beaumont, TX USA

[7] Univ Rochester, Dept Hematol Oncol, Rochester, NY USA

来源：

LEUKEMIA RESEARCH REPORTS | 2025年 / 23卷

关键词：

Acute myeloid leukemia; Revumenib; KMT2A; Menin inhibition therapy; INHIBITOR; REVUMENIB;

D O I：

10.1016/j.lrr.2024.100495

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective: This mini-review provides an overview of the current evidence for Revumenib, a first-in-class menin inhibitor, in treating AML with KMT2A rearrangements or NPM1 mutations. This therapy represents a promising advancement by selectively disrupting leukemogenic pathways. Summary: The clinical promise of Revumenib in genetically defined AML highlights its potential role in shaping the future treatment landscape. This mini-review underscores the need for ongoing trials to define optimal dosing, safety protocols, and combination therapies, with the ultimate goal of establishing Revumenib as a standard of care for high-risk AML subsets.

引用

收藏

页数：4

相关论文

共 27 条

[1] Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Ef cacy and Safety Results from the Pivotal Augment-101 Phase 2 Study [J].

Aldoss, Ibrahim ;

Issa, Ghayas C. ;

Thirman, Michael ;

DiPersio, John ;

Arellano, Martha ;

Blachly, James S. ;

Mannis, Gabriel N. ;

Perl, Alexander ;

Dickens, David S. ;

McMahon, Christine M. ;

Traer, Elie ;

Zwaan, C. Michel ;

Grove, Carolyn ;

Stone, Richard ;

Shami, Paul J. ;

Mantzaris, Ioannis ;

Greenwood, Matthew ;

Shukla, Neerav ;

Cuglievan, Branko ;

Gu, Yu ;

Bagley, Rebecca G. ;

Madigan, Kate ;

Sunkaraneni, Soujanya ;

Van Nguyen, Huy ;

McNeer, Nicole ;

Stein, Eytan M. .

BLOOD, 2023, 142

[2] Morphological and Immunophenotypic Clues to the WHO Categories of Acute Myeloid Leukaemia [J].

Bain, Barbara J. ;

Bene, Marie C. .

ACTA HAEMATOLOGICA, 2019, 141 (04) :232-244

[3]

Beat AML LLC, 2024, A Master Protocol for biomarker-based treatment of AML (The Beat AML Trial)

[4] Non-immunotherapy approaches for Relapsed or Refractory AML: an update for 2024 [J].

Buchrits, Shira ;

Wolach, Ofir .

ACTA HAEMATOLOGICA, 2024, 147 (02) :160-175

[5] Challenges and opportunities in targeting the menin- MLL interaction [J].

Cierpicki, Tomasz ;

Grembecka, Jolanta .

FUTURE MEDICINAL CHEMISTRY, 2014, 6 (04) :447-462

[6] Menin Inhibitor Induced Menin Protein Degradation Contributes to Menin Inhibitor Efficacy [J].

Cutler, Jevon ;

Tsai, Jonathan ;

Regalado, Brandon ;

Bourgeois, Wallace ;

Wenge, Daniela ;

Kim, Jeonghyeon ;

Nowak, Radoslaw ;

Ener, Elizabeth ;

Donovan, Katherine ;

Olsen, Sarah Naomi ;

Fischer, Eric ;

Ebert, Benjamin L. ;

Armstrong, Scott A. .

BLOOD, 2023, 142

[7]

Daver N, 2024, EHA 2024 ANN M, pS138

[8] Acute myeloid leukaemia [J].

Dinardo, Courtney D. ;

Erba, Harry P. ;

Freeman, Sylvie D. ;

Wei, Andrew H. .

LANCET, 2023, 401 (10393) :2073-2086

[9] Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia [J].

Erba, Harry P. ;

Fathi, Amir T. ;

Issa, Ghayas C. ;

Altman, Jessica K. ;

Montesinos, Pau ;

Patnaik, Mrinal M. ;

Foran, James M. ;

De Botton, Stephane ;

Baer, Maria R. ;

Schiller, Gary J. ;

Walter, Roland B. ;

Kremyanskaya, Marina ;

Pettit, Kristen M. ;

Strickland, Stephen A. ;

Tomkinson, Blake ;

Tabachri, Marilyn ;

Leoni, Mollie ;

Dale, Stephen ;

Wang, Eunice S. .

BLOOD, 2022, 140

[10] Revumenib (SNDX-5613): a promising menin inhibitor for the management of relapsed and refractory acute myeloid leukaemia (AML) [J].

Hussain, Harmla ;

Zaidi, Syeda Mahrukh Fatima ;

Hasan, Syed Mohammad ;

Jahan, Aelia Sarv ;

Rangwala, Burhanuddin Sohail ;

Rangwala, Hussain Sohail ;

Ali, Mirha ;

Farah, Asma Ahmed .

ANNALS OF MEDICINE AND SURGERY, 2024, 86 (05) :2379-2381